№ files_lp_3_process_7_059781
File format: docx
Character count: 11608
File size: 65 KB
The document provides updated guidelines for the coverage of the 4Kscore Test, a biomarker-based test for assessing high-grade prostate cancer, including FDA approval and prior reviews by the Health Evidence Review Commission.
Year:
2025
Region / City:
United States
Subject:
Prostate cancer biomarker test coverage
Document Type:
Guidelines
Organization:
Health Evidence Review Commission (HERC)
Author:
Health Evidence Review Commission (HERC)
Target Audience:
Healthcare providers, policymakers
Period of Validity:
2025 and ongoing
Approval Date:
December 2021
Date of Changes:
January 2025
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2026
Region / City:
N/A
Topic:
Prostate Brachytherapy Post-Treatment Care
Document Type:
Medical Instruction
Institution:
N/A
Author:
N/A
Target Audience:
Patients undergoing prostate HDR brachytherapy
Effective Period:
N/A
Approval Date:
N/A
Modification Date:
N/A
Year:
2011
Region / City:
United States
Topic:
Prostate Cancer, Disability Benefits
Document Type:
Questionnaire
Author:
REDACTED
Target Audience:
Veterans, Healthcare Providers
Period of Validity:
Not specified
Approval Date:
11/02/2010
Revision Date:
4/1/2011, 4/7/2011
Year:
2023
Region / City:
UK
Subject:
Decision Aid, BPH
Document Type:
Report
Organization / Institution:
NHS England
Author:
Winton Centre for Risk & Evidence Communication
Target Audience:
Clinicians, patients
Period of validity:
Not specified
Approval Date:
Not specified
Date of modifications:
Not specified
Year:
2024
Region:
Greater Manchester, UK
Topic:
Prostate cancer management
Document type:
Clinical protocol
Organization:
GM Cancer Urology Pathway Board
Author:
A Webber, GM Trusts subgroup
Target audience:
Healthcare professionals in urology and oncology
Date of review:
April 2024
Next review date:
April 2025
Version:
1.2
References:
NICE NG131 guidelines, BAUS guidelines, NHS Long Term Plan for Cancer, NHSE Personalised Care for Cancer Initiative, GM Cancer Plan
Year:
2026
Region / city:
N/A
Topic:
Prostate cancer trials
Document type:
Call for proposals
Organization / institution:
N/A
Author:
N/A
Target audience:
Researchers and healthcare professionals
Action period:
Until 13 February 2026
Approval date:
N/A
Date of amendments:
N/A
Organisation:
Canberra Health Services
Department:
Radiation Oncology Department
Document Type:
Clinical Procedure
Clinical Focus:
Prostate Fiducial Marker Implant
Patient Group:
Adult patients
Professional Scope:
Registered Nurses (RNs)
Standards Referenced:
Australian College of Perioperative Nurses (ACORN) Standards
Related Facility:
Canberra Hospital
Procedure Context:
Radiation therapy preparation
Setting:
Brachytherapy bunker theatre
Type:
Educational assessment
Subject:
Prostate cancer staging, pathology, and clinical management
Medical focus:
Oncology; Urology
Content format:
Multiple-choice questions and case-based scenarios
Key topics:
Gleason score; PSA testing; Clinical staging (cT); CS Extension codes; SSF codes; Prostatectomy findings; Active surveillance; Imaging modalities
Referenced source:
http://cancerbulletin.facs.org/forums/showthread.php?6644-SSF-12-amp-13-Prostate
Year:
2026
Organization:
Prostate Cancer Fight Foundation/Ride For Dad
Document Type:
Grant Application Form
Subject:
Prostate Cancer Research Funding
Application Deadline:
February 28, 2026
Submission Method:
Email submission of completed form
Contact Person:
Peter Wallace
Contact Email:
[email protected]
Eligible Applicants:
Principal Investigators and research teams
Geographic Scope:
Canada
Funding Restrictions:
No administrative costs permitted
Reporting Requirements:
Semi-annual and final project reports required for previous recipients
Public Disclosure:
Lay and scientific abstracts agreed to be publicly available
Additional Requirements:
Photo and brief bio sketch to be submitted separately
Year:
2026
Region:
Newfoundland and Labrador
Subject:
Prostate cancer research funding
Document Type:
Call for research proposals
Issuing Organization:
Prostate Cancer Fight Foundation (PCFF)
Partner Organization:
Ride For Dad (Avalon and Gander Chapters)
Total Funding Available:
$29,000
Typical Grant Value:
$20,000–$50,000
Grant Duration:
12 months
Application Deadline:
February 28, 2026
Eligible Applicants:
Individuals, academics, institutions, affiliated foundations
Purpose:
Support research or seed funding for new clinical initiatives related to prostate cancer
Prohibited Expenses:
Administration or overhead costs, equipment purchases, travel, sabbatical leaves, conferences, seminars, living expenses, general information pamphlets, for-profit projects
Reporting Requirements:
Public announcement within one month; 100-word public update every 6 months; final lay summary
Review Process:
Peer review by Medical Advisory Board
Fund Disbursement Period:
Within 12 months of award
Contact Person:
Peter Wallace, Co-Chair
Contact Email:
[email protected]
Website:
www.ridefordad.ca
Year:
2021
Region / city:
India
Topic:
Prostate Cancer Radiation Therapy
Document type:
Survey
Organization / institution:
N/A
Author:
N/A
Target audience:
Radiation Therapists
Effective period:
N/A
Approval date:
N/A
Date of amendments:
N/A
Year:
Not specified
Region / City:
Not specified
Topic:
Medical procedure, prostate biopsy
Document Type:
Consent form
Author:
Not specified
Target Audience:
Patients undergoing prostate biopsy
Period of Validity:
Not specified
Approval Date:
Not specified
Modification Date:
Not specified
Context:
A medical consent form outlining the risks, benefits, and procedure of transrectal ultrasound and prostate biopsy.
Year:
2026
Region / City:
Not specified
Topic:
Cancer genomics, epigenetics, prostate cancer
Document type:
Supplementary material
Institution:
Not specified
Authors:
Chennan Li et al.
Target audience:
Researchers in oncology and molecular biology
Sample type:
Plasma and buffy coat
Methods:
ctDNA sequencing, 5mC/5hmC methylomics, clonal reconstruction
Timepoints:
Baseline, restaging, progression, off-study
Genes analyzed:
AR, BRCA2, erythroid markers, platelet/megakaryocyte markers, globins
Data included:
Sequencing metrics, methylation percentages, gene-level events, survival analysis
Associated figures:
8 supplementary figures, 2 supplementary tables
Statistical analyses:
Spearman correlation, Kruskal-Wallis test, Mann-Whitney U test, Kaplan-Meier survival estimates, log-rank test
Year:
[Insert year]
Region / city:
[Insert region/city]
Subject:
Medical treatment request
Document type:
Authorization request letter
Institution:
[Insert institution name]
Author:
[Physician’s name]
Target audience:
Medical/Pharmacy Director
Effective period:
[Insert effective period]
Approval date:
[Insert approval date]
Date of modifications:
[Insert modification date]
Diagnosis:
[Insert diagnosis]
Treatment:
ERLEADA® (apalutamide)
Clinical trial:
TITAN trial
Clinical guidelines reference:
NCCN Guidelines®, AUA/SUO Guidelines
Patient history:
[Insert patient history]
Risk of disease progression:
[Insert risk]
Adverse reactions:
Rash, hot flush, hypertension, arthralgia, pruritus
Publication reference:
Journal of Clinical Oncology
Study data source:
Precision Point Specialty (PPS) Analytics, Komodo Research Database
Study design:
Retrospective, longitudinal, head-to-head analysis
Outcome:
Overall survival at 24 months
Document type:
Supplementary tables from a scientific research study
Research field:
Oncology; Cancer genomics
Disease focus:
Prostate cancer
Study design:
Retrospective cohort analysis
Cohorts included:
JHMI; Mayo; TJU; Durham; Kaiser; BWH; TCGA
Tissue type:
Radical prostatectomy specimens and biopsy samples
Total sample sizes:
Cohorts ranging from 100 to 355 patients
Clinical variables:
Age at diagnosis; PSA at diagnosis; Gleason Grade Group; ADT treatment status; metastatic outcome or recurrence; follow-up duration
Statistical measures:
Adjusted p-values after FDR multiple test correction; hazard ratios; confidence intervals; p-values
Genetic markers analyzed:
DNA repair signatures; immune cell signatures; mismatch repair genes; neuroendocrine markers; multiple individual genes (e.g., PMS2, MLH1, ESR1, SOX2)
Outcome measures:
Metastatic progression or recurrence
Statistical models:
Batch-stratified competing risks regression
Key variables in regression:
AR-A expression level; Gleason grade ≥8; surgical margins; PSA level; age at radical prostatectomy; ADT treatment type; extracapsular extension; seminal vesicle invasion; lymph node invasion
Follow-up period:
Median follow-up ranging from 28 to 108 months across cohorts
Year:
2023
Region / City:
USA
Subject:
Cancer Research, Prostate Cancer, Dietary Supplements
Document Type:
Research Article
Author:
Anait S. Levenson
Target Audience:
Researchers, Oncologists, Medical Professionals
Period of Action:
Not specified
Date of Approval:
Not specified
Date of Changes:
Not specified
Year:
2023
Region / City:
-
Subject:
Immunology, Diagnostic Assay
Document Type:
Technical Manual
Organization:
-
Author:
-
Target Audience:
Laboratory Professionals
Period of Validity:
-
Approval Date:
-
Modification Date:
-
Year:
Not specified
Region / City:
Not specified
Thematic Area:
Criminology, Criminal Investigation
Document Type:
Examination Syllabus
Author:
Not specified
Target Audience:
Criminology students or professionals preparing for the board exam
Validity Period:
Not specified
Approval Date:
Not specified
Amendment Date:
Not specified
Region:
North West England
Subject:
Fetal growth restriction; small for gestational age; antenatal and postnatal care
Document type:
Regional clinical guideline
Version:
1.1
Issue date:
August 2019
Ratification date:
25 January 2019
Approving body:
GMEC SCN Maternity Steering Group
Issuing body:
North West FGR Network
Authors:
Ed Johnstone; Suzanne Thomas; Emma Ingram
Intended audience:
All staff
Related pathway:
North West eFGR Integrated Care Pathway
Review date:
22 March 2021
Scope:
Risk assessment, antenatal management, delivery planning, postnatal management
Geographical applicability:
North West region
Year:
2010
Region / City:
N/A
Topic:
Fault Detection, Gearbox Systems
Document Type:
Technical Description
Organization / Institution:
PHM Society
Author:
N/A
Target Audience:
Researchers, Engineers
Period of Validity:
N/A
Approval Date:
N/A
Modification Date:
N/A
Year:
2025
Region / City:
Global
Subject:
Drone Detection Technology
Document Type:
Technical Specifications
Organization / Institution:
Manufacturer (unspecified)
Author:
(unspecified)
Target Audience:
Drone security professionals, law enforcement agencies, security personnel
Validity Period:
(unspecified)
Approval Date:
(unspecified)
Amendment Date:
(unspecified)
Description:
Technical specifications for a portable device designed to detect and intercept FPV drone transmissions, aimed at ensuring airspace security.